Microsoft PowerPoint - Slides AIDIC da inviarebusiness opportunities Paolo Barbanti Biopharmaceutical manufacturing NCE's launched per year 30 35 40 45 50 55 60 65 85 86 87 88 89 90 91 92 93 94 95 96 97 98 0 5 10 15 20 25 30 35 40 Paolo Barbanti Biopharmaceutical manufacturing •patent expiry •time to market •need new products •consolidation •cash rich •provide innovation •need cash Paolo Barbanti Biopharmaceutical manufacturing Paolo Barbanti Biopharmaceutical manufacturing Combinatorial Chemistry Molecular Pharmacology Molecular Biology Paolo Barbanti Biopharmaceutical manufacturing State Agencies Paolo Barbanti Biopharmaceutical manufacturing Shorter preclinical development time and lower cost for monoclonal antibodies Paolo Barbanti Biopharmaceutical manufacturing CNS 3% ID 9% Oncology 52% AIID 22% Respiratory 6% CV 3% Other 5% Paolo Barbanti Biopharmaceutical manufacturing Top 12 biotechnology countries
